UBS Group AG Buys 4,162,433 Shares of Amicus Therapeutics, Inc. $FOLD

UBS Group AG increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 240.5% during the 4th quarter, Holdings Channel reports. The firm owned 5,893,288 shares of the biopharmaceutical company’s stock after purchasing an additional 4,162,433 shares during the quarter. UBS Group AG’s holdings in Amicus Therapeutics were worth $83,920,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Ion Asset Management Ltd. bought a new position in Amicus Therapeutics during the third quarter valued at approximately $6,875,000. CIBRA Capital Ltd bought a new position in Amicus Therapeutics during the fourth quarter valued at approximately $3,002,000. Elevation Point Wealth Partners LLC bought a new position in Amicus Therapeutics during the third quarter valued at approximately $2,961,000. SG Americas Securities LLC grew its position in Amicus Therapeutics by 53.2% during the fourth quarter. SG Americas Securities LLC now owns 106,358 shares of the biopharmaceutical company’s stock valued at $1,515,000 after acquiring an additional 36,938 shares during the last quarter. Finally, Nordea Investment Management AB bought a new position in Amicus Therapeutics during the third quarter valued at approximately $7,843,000.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 22,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total transaction of $322,875.00. Following the completion of the sale, the chief executive officer owned 998,680 shares of the company’s stock, valued at approximately $14,331,058. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on FOLD. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Friday, March 27th. Jefferies Financial Group reiterated a “hold” rating and set a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Guggenheim cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Finally, Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Amicus Therapeutics has a consensus rating of “Hold” and an average price target of $14.56.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $14.49 on Monday. The firm has a market cap of $4.55 billion, a PE ratio of -181.13 and a beta of 0.48. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $14.50. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.88 and a current ratio of 2.84. The business has a 50 day moving average price of $14.42 and a 200-day moving average price of $12.72.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). The company had revenue of $185.21 million for the quarter, compared to analysts’ expectations of $185.00 million. Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business’s revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period last year, the company posted $0.09 EPS. Equities research analysts predict that Amicus Therapeutics, Inc. will post 0.43 earnings per share for the current year.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.